In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity

Limosilactobacillus reuteri INIA P572 is a strain able to produce the antimicrobial compound reuterin in dairy products, exhibiting a protective effect against some food-borne pathogens. In this study, we investigated some probiotic properties of this strain such as resistance to gastrointestinal passage or to colonic conditions, reuterin production in a colonic environment, and immunomodulatory activity, using different in vitro and in vivo models. The results showed a high resistance of this strain to gastrointestinal conditions, as well as capacity to grow and produce reuterin in a human colonic model. Although the in vitro assays using the RAW 264.7 macrophage cell line did not demonstrate direct immunomodulatory properties, the in vivo assays using a Dextran Sulphate Sodium (DSS)-induced colitic mice model showed clear immunomodulatory and protective effects of this strain.

Download Full-text

The immunomodulatory activity of SerpinB3 an protease-inhibitor in vivo and in vitro

Digestive and Liver Disease ◽

10.1016/j.dld.2017.01.056 ◽

2017 ◽

Vol 49 (1) ◽

pp. e26

Author(s):

A. Cappon ◽

G. Villano ◽

S. Quarta ◽

A. Biasiolo ◽

C. Turato ◽

...

Keyword(s):

Protease Inhibitor ◽

Immunomodulatory Activity

Download Full-text

Surface-Engineered Dendrimeric Nanoconjugates for Macrophage-Targeted Delivery of Amphotericin B: Formulation Development andIn VitroandIn VivoEvaluation

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.04213-14 ◽

2015 ◽

Vol 59 (5) ◽

pp. 2479-2487 ◽

Cited By ~ 40

Author(s):

Keerti Jain ◽

Ashwni Kumar Verma ◽

Prabhat Ranjan Mishra ◽

Narendra Kumar Jain

Keyword(s):

Drug Release ◽

Amphotericin B ◽

Human Erythrocytes ◽

Antileishmanial Activity ◽

Cell Uptake ◽

Antiparasitic Activity ◽

Content Type ◽

Drug Localization

ABSTRACTThe present study aimed to develop an optimized dendrimeric delivery system for amphotericin B (AmB). Fifth-generation (5.0G) poly(propylene imine) (PPI) dendrimers were synthesized, conjugated with mannose, and characterized by use of various analytical techniques, including Fourier transform infrared spectroscopy (FTIR),1H nuclear magnetic resonance (1H-NMR) spectroscopic analysis, and atomic force microscopy (AFM). Mannose-conjugated 5.0G PPI (MPPI) dendrimers were loaded with AmB and evaluated for drug loading efficiency,in vitrodrug release profile, stability, hemolytic toxicity to human erythrocytes, cytotoxicity to and cell uptake by J774A.1 macrophage cells, antiparasitic activity against intracellularLeishmania donovaniamastigotes,in vivopharmacokinetic and biodistribution profiles, drug localization index, toxicity, and antileishmanial activity. AFM showed the nanometric size of the MPPI dendrimers, with a nearly globular architecture. The conjugate showed a good entrapment efficiency for AmB, along with pH-sensitive drug release. Highly significant reductions in toxicity toward human erythrocytes and macrophage cells, without compromising the antiparasitic activity of AmB, were observed. The dendrimeric formulation of AmB showed a significant enhancement of the parasiticidal activity of AmB toward intramacrophagicL. donovaniamastigotes. In thein vitrocell uptake studies, the formulation showed selectivity toward macrophages, with significant intracellular uptake. Further pharmacokinetic and organ distribution studies elucidated the controlled delivery behavior of the formulation. The drug localization index was found to increase significantly in macrophage-rich organs.In vivostudies showed a biocompatible behavior of MPPIA, with negligible toxicity even at higher doses, and promising antileishmanial activity. From the results, we concluded that surface-engineered dendrimers may serve as optimized delivery vehicles for AmB with enhanced activity and low or negligible toxicity.

Download Full-text

Effects of Bothrops asper snake venom on the expression of cyclooxygenases and production of prostaglandins by peritoneal leukocytes in vivo, and by isolated neutrophils and macrophages in vitro

Prostaglandins Leukotrienes and Essential Fatty Acids ◽

10.1016/j.plefa.2008.11.009 ◽

2009 ◽

Vol 80 (2-3) ◽

pp. 107-114 ◽

Cited By ~ 14

Author(s):

Vanessa Moreira ◽

José María Gutiérrez ◽

Rafaela Bacci Amaral ◽

Stella Regina Zamunér ◽

Catarina de Fátima Pereira Teixeira

Keyword(s):

Snake Venom ◽

Peritoneal Leukocytes ◽

Bothrops Asper

Download Full-text

In Vitro Antileishmanial Activity of Nicotinamide

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.49.2.808-812.2005 ◽

2005 ◽

Vol 49 (2) ◽

pp. 808-812 ◽

Cited By ~ 35

Author(s):

D. Sereno ◽

A. Monte Alegre ◽

R. Silvestre ◽

B. Vergnes ◽

A. Ouaissi

Keyword(s):

Leishmania Major ◽

Growth Arrest ◽

Antileishmanial Activity ◽

Vitamin B ◽

Wild Type ◽

Intracellular Growth ◽

Cell Growth Arrest ◽

Transgenic Parasites

ABSTRACT Our study represents the first report demonstrating the antileishmanial activity of nicotinamide (NAm), a form of vitamin B3. A 5 mM concentration of NAm significantly inhibited the intracellular growth of Leishmania amastigotes and the NAD-dependent deacetylase activity carried by parasites overexpressing Leishmania major SIR2 (LmSIR2). However, the transgenic parasites were as susceptible as the wild-type parasites to NAm-induced cell growth arrest. Therefore, we conclude that NAm inhibits leishmanial growth and that overexpression of LmSIR2 does not overcome this inhibition. The mechanism of the inhibition is not defined but may include other in vivo targets. NAm may thus represent a new antileishmanial agent which could potentially be used in combination with other drugs during therapy.

Download Full-text

766 Toward safe, systemic delivery of synthetic TLR7/8 agonists using Bottlebrush Prodrugs (BPDs)

Journal for ImmunoTherapy of Cancer ◽

10.1136/jitc-2021-sitc2021.766 ◽

2021 ◽

Vol 9 (Suppl 3) ◽

pp. A801-A801

Author(s):

Sachin Bhagchandani ◽

Lauren Milling ◽

Bin Liu ◽

Timothy Fessenden ◽

Stefani Spranger ◽

...

Keyword(s):

Survival Rates ◽

Immunomodulatory Activity ◽

Systemic Delivery ◽

Antibody Treatment ◽

Tlr Agonists ◽

Cytokine Levels ◽

Systemic Side Effects ◽

Tolerable Dose

BackgroundAlthough toll-like receptor (TLR) agonists such as imidazoquinoline derivatives (IMDs) have been well researched and are FDA approved as topical solutions for treatment of skin cancer, their systemic delivery for treatment of metastatic disease has not been successful due to toxicity issues. Therefore, to lessen the degree of the adverse effects of intravenous delivery of IMDs such as resiquimod (R848), a bottlebrush prodrug (BPD) system enabling controlled release of R848 at tunable rates was designed and synthesized. We hypothesized that this approach would allow for minimizing the release of the free drug in serum, allowing for a higher concentration to accumulate in the tumor while minimizing systemic side effects.MethodsR848 was conjugated to a bottlebrush polymer with different linkers designed to precisely tune the R848 release rate. The release rates of the drug delivered through this system were first tested in PBS. These prodrug formulations were validated for drug activity in vitro in mouse and human TLR reporter cells. The maximum tolerable dose was defined by monitoring weight loss and serum cytokine levels upon intravenous administration at multiple concentrations. Finally, anti-tumor efficacy of the BPD system was tested in vivo using the MC38 colon cancer model as a monotherapy and in combination with anti-PD-1 antibody treatment.ResultsThe in-vitro half-lives of the conjugated drugs varied from a few days to over a month when tested in PBS. The different BPDs demonstrated linker dependent TLR activation upon culturing with TLR reporter cells validating the immunomodulatory activity of R848. It was found that the R848-BPDs, which accumulated at the tumor site over time, significantly delayed tumor growth and improved survival rates, which was further enhanced when used in combination with anti-PD-1.ConclusionsOverall, our research suggests that our R848-BPD platform allows for safe, systemic delivery of TLR agonists to activate the immune system in treatment of cancer.

Download Full-text

ASSESSMENT OF SNAKE ANTIVENOM ACTIVITY OF TAMARINDUS INDICA SEED COAT EXTRACT

International Journal of Advanced Research ◽

10.21474/ijar01/13438 ◽

2021 ◽

Vol 9 (09) ◽

pp. 489-497

Author(s):

Priyanka D. Mundhe ◽

◽

Balasaheb S. Pawade ◽

Indrasen G. Waykar ◽

Innus K. Shaikh ◽

...

Keyword(s):

Snake Venom ◽

Seed Coat ◽

Rural Areas ◽

Proteolytic Enzymes ◽

Lethal Dose ◽

Medical Emergency ◽

Dependent Manner ◽

Tamarindus Indica

Snakebite is a life-threatening medical emergency, and globally responsible for millions of deaths. In snakebites accidents only deaths are not a concern, it leads to more morbidities. Due to scanty healthcare facilities in rural areas of India, many people seek alternative treatment available in ethnic practices. Tamarindus Indica (TI) plant is rich in medicinal value and used to treat many diseases including snakebite treatment traditionally. In view of this TI seed coat extract (TISCE) was evaluated for antivenom activity. The phytochemical screening of TISCE was performed to understand its chemical composition. TISCE was evaluated for antivenom activity against Indian cobra venom (ICV), common krait venom (CKV), Russells viper venom (RVV), and saw-scaled viper venom (SCV) for phospholipase A2 (PLA-2), haemorrhagic in vitro and in vivo, procoagulant, proteolytic activity, and lethality studies. TISCE majorly contains saponins, glycosides, alkaloids, and phenolic compounds. Minimum indirect haemorrhagic dose (MIHD) observed for ICV (12.5 Âµg), CKV (5.0 Âµg),RVV (10.0 Âµg), and SVV (12.5 Âµg). TISCE inhibits the procoagulant activity of all venoms at a concentration of 18.0 Âµg. It also shows the neutralization of proteolytic enzymes of venom in a dose-dependent manner. A pre-incubated mixture containing five lethal dose 50 (LD50) of venom and TISCE was injected intravenously, all mice survived as venom neutralized by TISCE. The present study demonstrates the ability of TISCE to neutralize snake venom using suitable in vivo and in vitro methods. Further studies required to unravelling the speciï¬c active chemical constituent of TISCE that may used as novel alternative snakebite treatment. TISCE was able to prolong the deaths during the simulation study and may be used in the topical pharmaceutical formulation that will reduce local venom reactions causing much morbidity, which will collectively with Anti-snake venom (ASV), used to treat envenomed patients more effectively.

Download Full-text